FATE THERAPEUTICS, I

FATE

Delayed - 02/26 04:00:00 pm
89.72USD	+4.00%

05/12/21	Q1 2021 Earnings Release (Projected)
08/09/21	Interim 2021 Earnings Release (Projected)
11/10/21	Q3 2021 Earnings Release (Projected)
03/07/22	FY 2021 Earnings Release (Projected)

02/24/21 \| 05:00pm	FY 2020 Earnings Call
02/24/21	FY 2020 Earnings Release
12/05/20	American Society of Hematology Meeting
12/04/20 \| 04:30pm	Business Update Call

02/26/21 \| 04:35pm	REGENERON PHARMACEUTICALS, INC. : American Academy of Allergy, Asthma and Immunology Virtual Meeting - Poster 010
02/26/21	REGENERON PHARMACEUTICALS, INC. : American Academy of Allergy, Asthma and Immunology Virtual Meeting - Poster 290
02/26/21	REGENERON PHARMACEUTICALS, INC. : American Academy of Allergy, Asthma and Immunology Virtual Meeting - Poster 447
02/26/21	REGENERON PHARMACEUTICALS, INC. : American Academy of Allergy, Asthma and Immunology Virtual Meeting - Poster 425

02/25/21 \| 01:40pm	GILEAD SCIENCES, INC. : SVB Leerink Global Healthcare Conference
02/25/21 \| 01:40pm	EXACT SCIENCES CORPORATION : SVB Leerink Global Healthcare Conference
02/25/21	IOVANCE BIOTHERAPEUTICS, INC. : FY 2020 Earnings Release
02/25/21	VIR BIOTECHNOLOGY, INC. : FY 2020 Earnings Release

Previous year

Next Year

Annual results		2016	2017	2018	2019	2020	2021 (e)
Sales M $	Released Forecast Spread	4,40 4,35 1,1%	4,11 4,02 2,2%	4,74 4,08 16%	10,7 9,62 11%	31,4 21,2 48%	26,2
Operating income (EBITDA) M $	Released Forecast Spread	-32,0 -33,1 3,5%	-42,1 -40,8 -3,3%	-67,1 -65,9 -1,7%	-101 -99,9 -0,82%	-128 -130 1,3%	-177
Operating profit (EBIT) M $	Released Forecast Spread	-33,5 -34,9 4,1%	-43,0 -41,5 -3,4%	-66,6 -65,6 -1,5%	-98,1 -97,4 -0,72%	-173 -148 -17%	-171
Pre-Tax Profit (EBT) M $	Released Forecast Spread	-33,5 -35,0 4,3%	-43,0 -41,6 -3,3%	-66,6 -66,0 -0,98%	-98,1 -97,8 -0,40%	-173 -149 -17%	-169
Net income $	Released Forecast Spread	-1,05 -1,14 7,5%	-1,02 -0,97 -5,2%	-1,19 -1,18 -0,73%	-1,44 -1,44 0,21%	-2,10 -1,84 -14%	-1,81
Announcement Date		03/16/2017	03/05/2018	03/05/2019	03/02/2020	02/24/2021

Previous period

Next period

Quarterly results		2018 Q3	2018 Q4	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1 (e)	2021 Q2 (e)	2021 Q3 (e)	2021 Q4 (e)	2022 Q1 (e)
Sales M $	Released Forecast Spread	1,03 1,24 -17%	1,66 1,02 63%	2,63 2,01 31%	2,82 1,09 159%	2,43 1,75 38%	2,80 1,70 65%	2,52 1,69 49%	5,47 10,9 -50%	7,56 7,49 0,90%	15,9 5,64 182%	6,49	6,52	6,70	6,76	8,75
Operating income (EBITDA) M $	Released Forecast Spread	-16,7 -13,9 -20%	-16,7 -18,0 7,2%	-20,4 -16,3 -25%	-24,1 -22,5 -7,0%	-27,1 -25,6 -6,1%	-29,1 -28,3 -2,6%	-34,5 -30,1 -15%	-28,7 -22,3 -29%	-31,5 -28,3 -11%	-33,4 -35,1 4,7%	-41,0	-43,0	-44,8	-47,4	-58,5
Operating profit (EBIT) M $	Released Forecast Spread	-16,8 -13,9 -21%	-16,0 -18,2 12%	-19,8 -15,8 -25%	-23,5 -21,7 -8,3%	-26,6 -25,3 -5,0%	-28,3 -27,9 -1,3%	-33,5 -29,7 -13%	-28,1 -21,1 -33%	-58,7 -27,2 -116%	-53,1 -35,2 -51%	-40,4	-40,9	-43,0	-46,4
Pre-Tax Profit (EBT) M $	Released Forecast Spread	-16,8 -16,2 -3,4%	-16,0 -18,0 11%	-19,8 -16,2 -22%	-23,5 -21,7 -8,1%	-26,6 -25,5 -4,5%	-28,3 -28,2 -0,23%	-33,5 -29,3 -15%	-28,1 -21,6 -30%	-58,7 -27,2 -116%	-53,1 -35,4 -50%	-39,3	-40,5	-42,3	-45,8	-58,0
Net income $	Released Forecast Spread	-0,31 -0,25 -25%	-0,25 -0,25 0,79%	-0,30 -0,23 -29%	-0,36 -0,33 -10%	-0,40 -0,38 -5,3%	-0,37 -0,39 4,9%	-0,44 -0,39 -13%	-0,35 -0,29 -22%	-0,68 -0,32 -110%	-0,61 -0,41 -50%	-0,43	-0,44	-0,46	-0,49	-0,60
Announcement Date		11/01/2018	03/05/2019	05/07/2019	08/06/2019	11/05/2019	03/02/2020	05/11/2020	08/05/2020	11/05/2020	02/24/2021